Throughout the course of the projected period, an increase in the prevalence of mental diseases is anticipated to fuel market expansion for sertraline HCl globally. For instance, the National Institute of Mental Health reported in January 2022 that 21.0 million adults in the United States experienced at least one major depressive episode in the previous year. In 2020, this figure accounted for 8.4% of all adults in the US. The expansion of the worldwide sertraline HCl market is anticipated to be driven by an increase in product releases for the drug. For instance, in November 2021, Camber Pharmaceuticals, a fully integrated global pharmaceutical business, declared that sertraline hydrochloride tablets, the generic form of Zoloft, had been introduced to their current line of products.
The global Sertraline HCl Market is estimated to be valued at US$ 1,385.9 million in 2022 and is expected to exhibit a CAGR of 7.1% during the forecast period (2022-2030).
Top Companies in the Sertraline HCl Industry:
1. Pfizer Inc.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. on December 2022, Pfizer Presents Updated Favorable Elranatamab Data from Pivotal Phase 2 MagnetisMM-3 Trial, early and deep responses, and a manageable safety profile for elranatamab in heavily pretreated patients with advanced multiple myeloma.
2. Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
3. Novartis International AG
Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. The company operates through two segments: Innovative Medicines and Sandoz. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol.
